Gene · 2181
Papers1,288
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 1,288
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A lymph node-targeted nanoplatform reprograms metabolic and immune microenvironments via dual ACSL3/4 inhibition in lymphatic metastatic tumors. | J Control Release | 2026 | 42822540 | PubTator, text mining | PubMed |
| Lipidome as a ferroptotic rheostat in cholangiocarcinoma: A proposed model and its current evidence base. | Mol Biol Rep | 2026 | 42801336 | PubTator, text mining | PubMed |
| ZDHHC9 regulates lipid metabolic reprogramming by mediating palmitoylation of ACSL3 to promote cetuximab resistance in colorectal cancer. | Exp Cell Res | 2026 | 42790666 | PubTator, text mining | PubMed |
| Targeting lipid metabolism-associated lncHMGCS1 suppressed cell proliferation and restored intracellular lipid homeostasis by regulating ACSL3 in gastric cancer. | Eur J Pharmacol | 2026 | 42722057 | PubTator, text mining | PubMed |
| ACSL3 at the UPR crossroads: Tactician of anti-influenza defense, target of influenza offense. | Virol Sin | 2026 | 42697439 | PubTator, text mining | PubMed |
| Linoleic acid metabolic reprogramming is linked to immunometabolic remodeling and post-transplant recurrence risk in hepatocellular carcinoma. | Front Immunol | 2026 | 42643672 | PubTator, text mining | PubMed |
| Targeting the PHB2-ACSL3 Lipid-Remodeling Axis Overcomes Cisplatin Resistance by Restoring Ferroptosis in Gastric Cancer. | Adv Sci (Weinh) | 2026 | 42627686 | PubTator, text mining | PubMed |
| CSF1 inhibits ferroptosis in colorectal cancer cells by autocrine activation of the JAK/STAT3 signaling pathway. | Biochem Pharmacol | 2026 | 42526771 | PubTator, text mining | PubMed |
| Targeting NAE1 suppresses osteoclastogenesis via dual regulation of ferritinophagy and ACSL3-mediated ferroptosis. | Autophagy | 2026 | 42495964 | PubTator, text mining | PubMed |
| Toward pharmacologic therapy for glioblastoma: Characterization of the very long-chain acyl-CoA synthetase 3 (ACSVL3) inhibitor Grassofermata. | bioRxiv | 2026 | 42465312 | PubTator, text mining | PubMed |
| PLIN1 restoration modulates lipid reprogramming and impedes tumor growth in ovarian cancer. | BMC Cancer | 2026 | 42414938 | PubTator, text mining | PubMed |
| ACSL3 inhibits ferroptosis in gastric cancer through the activation of unfolded protein response following endoplasmic reticulum stress. | Cell Death Dis | 2026 | 42414261 | PubTator, text mining | PubMed |
| SIRT7-mediated ACSL3 delactylation suppresses colorectal cancer progression by orchestrating tumor-associated macrophage ferroptosis and polarization. | Cell Death Dis | 2026 | 42380090 | PubTator, text mining | PubMed |
| Structural and functional characterization of Acyl-CoA Synthetase Long-Chain Family Member 3 (ACSL3) and its targeted inhibition by gramicidin in multiple myeloma. | Int J Biol Macromol | 2026 | 42320818 | PubTator, text mining | PubMed |
| YTHDF1 enhances ACSL3 translation in an m6A-dependent manner to regulate lipid metabolism and colorectal cancer progression. | Transl Cancer Res | 2026 | 42305514 | PubTator, text mining | PubMed |
| Degradation of ACSL3 by influenza A virus shifts unfolded protein response from antiviral defense to viral evasion. | Virol Sin | 2026 | 42288136 | PubTator, text mining | PubMed |
| Targeting Ferroptosis for Cerebral Neuroprotection in Ischemic Stroke: Pathophysiological Insights. | Int J Gen Med | 2026 | 42221841 | PubTator, text mining | PubMed |
| Multiomic and functional validation of ACSL3, a regulator of fatty acid metabolism, as a lymph node metastasis-associated gene in lung adenocarcinoma. | Respir Res | 2026 | 41998631 | PubTator, text mining | PubMed |
| NT5DC2 inhibits ferroptosis by stabilizing ACSL3 in bladder cancer. | Cell Death Discov | 2026 | 41974665 | PubTator, text mining | PubMed |
| Ferroptosis in Glioblastoma and Neuroblastoma: Molecular Mechanisms and Novel Therapeutic Strategies. | Curr Issues Mol Biol | 2026 | 41899419 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2181/papers